Publications by authors named "Ya-Nan Wen"
[Prognostic Value of Gene Expression Levels in Patients with Acute Myeloid Leukemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
April 2024
Article Synopsis
- The study aimed to explore how gene expression relates to the prognosis of acute myeloid leukemia (AML) patients by analyzing bone marrow cells from 27 individuals and comparing results with healthy subjects and different AML patient groups.
- Results show that patients with refractory AML had significantly higher levels of a specific gene compared to those responsive to chemotherapy, and those with extramedullary infiltration also exhibited increased gene expression.
- Analysis revealed that resistant leukemia cell lines expressed more of the gene at both mRNA and protein levels compared to sensitive cell lines, suggesting a potential link between this gene and treatment resistance in AML.
[Venetoclax Combined with CACAG Regimen in the Treatment of Patients with Refractory/Relapse Acute Myeloid Leukemia: A Prospective Clinical Study].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
February 2024
Objective: To investigate the efficacy and safety of Venetoclax combined with CACAG regimen in treatment of patients with refractory/relapse acute myeloid leukemia(R/R AML).
Methods: The study was a singlecenter prospective clinical trial. The enrolled patients met the criteria for R/R AML.
Background: Acute myeloid leukemia (AML) is a heterogeneous hematopoietic malignancy. Patient prognosis cannot be accurately assessed in National Comprehensive Cancer Network (NCCN) risk stratification subgroups based on the current criteria. This study aimed to develop a novel prognostic score model for the quantitative prediction of prognosis in AML.
View Article and Find Full Text PDF[Kinetics of MDSC in Patients Treated Steroids-Ruxolitinib as the First Line Therapy for aGVHD].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
February 2022
Article Synopsis
- The study aimed to assess lymphocyte subsets and myeloid-derived suppressor cells (MDSC) in patients with newly diagnosed intermediate- to high-risk acute graft-versus-host disease (aGVHD) treated with steroids and ruxolitinib.
- Out of 23 patients treated, the complete response rate was 78.26% after 28 days, with observed changes in certain lymphocyte levels, indicating a potential treatment response.
- The researchers found significant differences in MDSC levels between patients with and without aGVHD, suggesting the effectiveness of the steroids-ruxolitinib treatment in modifying immune cell activity in these patients.